{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:22:58Z","timestamp":1789554178648,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.thromres.2012.08.280","type":"journal-article","created":{"date-parts":[[2012,9,29]],"date-time":"2012-09-29T00:03:55Z","timestamp":1348877035000},"page":"S66-S70","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S1","title":["Adjuvant therapy in breast cancer and venous thromboembolism"],"prefix":"10.1016","volume":"130","author":[{"given":"Mario","family":"Mandal\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tondini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2012.08.280_bb0005","first-page":"94","article-title":"Phlegmasia alba dolens","volume":"vol. 3","author":"Trousseau","year":"1865"},{"key":"10.1016\/j.thromres.2012.08.280_bb0010","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archinte.165.10.1173","article-title":"Prospective evaluation of health-related quality of life in patients with deep venous thrombosis","volume":"165","author":"Kahn","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2012.08.280_bb0015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdi165","article-title":"Deep vein thrombosis in cancer: the scale of the problem and approaches to management","volume":"16","author":"Falanga","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.08.280_bb0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2012.08.280_bb0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2008.09.005","article-title":"Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule study findings","volume":"45","author":"Mandala","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.thromres.2012.08.280_bb0035","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2012.08.280_bb0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2006.07.4393","article-title":"Incidence of venous thromboembolism and the impact on survival in breast cancer patients","volume":"25","author":"Chew","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0045","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1200\/JCO.1994.12.6.1266","article-title":"Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study","volume":"12","author":"Clahsen","year":"1994","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.thromres.2012.08.280_bb0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM198802183180703","article-title":"The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer","volume":"318","author":"Levine","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.280_bb0055","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0002-8703(96)90321-X","article-title":"Cancer and venous thromboembolism","volume":"132","author":"Piccioli","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2012.08.280_bb0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.critrevonc.2006.05.001","article-title":"Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM)","volume":"59","author":"Mandala","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.breast.2010.09.001","article-title":"The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer","volume":"20","author":"Nolan","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.thromres.2012.08.280_bb0070","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"The ATAC Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2012.08.280_bb0075","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0080","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.thromres.2012.08.280_bb0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2011.11.025","article-title":"Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: A population-based experience","volume":"130","author":"Onitilo","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2012.08.280_bb0090","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1002\/cncr.24508","article-title":"Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study","volume":"115","author":"Hernandez","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2012.08.280_bb0095","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.thromres.2012.08.280_bb0100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","article-title":"A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors","volume":"320","author":"Fisher","year":"1989","journal-title":"New Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.280_bb0105","first-page":"119","article-title":"Tamoxifen versus placebo: double blind adjuvant trial in elderly women with stage II breast cancer","volume":"1","author":"Cummings","year":"1986","journal-title":"NCI Monogr"},{"key":"10.1016\/j.thromres.2012.08.280_bb0115","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.1996.14.10.2731","article-title":"Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group","volume":"14","author":"Pritchard","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0120","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.1991.9.2.286","article-title":"Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer","volume":"9","author":"Saphner","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0125","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1001\/archinte.1996.00440150056006","article-title":"Effect of tamoxifen on measurements of hemostasis in healthy women","volume":"156","author":"Mannucci","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2012.08.280_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181faa0f2","article-title":"Leiden thrombophilia","volume":"13","author":"Kujovich","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.thromres.2012.08.280_bb0135","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<2024::AID-CNCR25>3.0.CO;2-V","article-title":"Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden","volume":"79","author":"Weitz","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2012.08.280_bb0140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0014-2964(79)90097-5","article-title":"Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer","volume":"15","author":"Pannuti","year":"1979","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.thromres.2012.08.280_bb0145","first-page":"44","article-title":"High dose megestrol acetate in the treatment of advanced breast cancer","volume":"15","author":"Tchekmedyian","year":"1988","journal-title":"Semin Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0150","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer\u201396-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.thromres.2012.08.280_bb0155","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jnci\/djq211","article-title":"Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer","volume":"102","author":"Garber","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.thromres.2012.08.280_bb0160","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/jnci\/djj262","article-title":"Effect of Factor V Leiden and prothrombin G20210\u2013>A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial","volume":"98","author":"Abramson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.thromres.2012.08.280_bb0165","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1200\/JCO.2003.10.111","article-title":"Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0170","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2012.08.280_bb0175","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.thromres.2012.08.280_bb0180","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.1994.12.10.2078","article-title":"Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study","volume":"12","author":"Rivkin","year":"1994","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.thromres.2012.08.280_bb0185","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.1990.8.6.1005","volume":"8","author":"Fisher","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM198902233200804","article-title":"Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node negative breast cancer","volume":"320","author":"Ludwig Breast Cancer Study Group","year":"1989","journal-title":"New Engl J Med"},{"key":"10.1016\/j.thromres.2012.08.280_bb0195","first-page":"677","article-title":"Venous thrombosis during multimodel treatment of primary breast carcinoma","volume":"65","author":"Weiss","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.thromres.2012.08.280_bb0200","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","article-title":"Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer","volume":"89","author":"Fisher","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.thromres.2012.08.280_bb0205","first-page":"75","article-title":"Postoperative chemotherapy and chemohormonal therapy in women with node positive breast cancer","volume":"1","author":"Tormey","year":"1986","journal-title":"NCI Monogr"},{"key":"10.1016\/j.thromres.2012.08.280_bb0210","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1200\/JCO.1999.17.7.1988","article-title":"Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group","volume":"17","author":"Wils","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0215","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/jnci\/85.17.1398","article-title":"Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group","volume":"85","author":"Rutqvist","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.thromres.2012.08.280_bb0220","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/bmj.311.7011.977","article-title":"Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group","volume":"311","author":"McDonald","year":"1995","journal-title":"Br Med J"},{"key":"10.1016\/j.thromres.2012.08.280_bb0225","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2012.08.280_bb0230","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdr524","article-title":"Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'","volume":"23","author":"Mandala","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.thromres.2012.08.280_bb0235","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2012.08.280_bb0240","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812006524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812006524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T12:28:06Z","timestamp":1542716886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384812006524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":47,"alternative-id":["S0049384812006524"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2012.08.280","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}